The role of Th17/Treg balance and Th22 cell in the pathogenesis of DSS-induced colitis in mice

Abstract

T-helper (Th) cells play a critical role in inflammatory bowel disease (IBD), especially the two new types: Th17 and Th22. But whether they are protective or pathogenic in the gut is still controversial. Unlike them, regulatory T (Treg) cells have undoubtedly suppressive function and can maintain immune homeostasis. Our current aims were to examine the change of Treg/Th17 balance, Th22 proportion, and the expression of Th17-related and/or Th22-related cytokines in inflammatory bowel disease. In this study, 3% dextran sulphate sodium (DSS) was administered orally to C57BL/6 mice to induce colitis. The morbidity was evaluated by daily body weight, colon length, disease activity index, and histology score of colonic lesions. Th17, Th22, and Treg cells were measured using flow cytometry. IL-17A, IL-17F, and IL-22 were quantified using enzyme linked immunosorbent assay (ELISA) kits. DSS administration induced severe clinical manifestations, such as body weight loss, colon shortening, relatively high disease activity index, and histological damage in colitis mice. Both CD4⁺IL-17A⁺IL-22⁻ cells and CD4⁺IL-22⁺IL-17A⁻ cells were significantly increased, which associated with the increasing expression of IL-17A, IL-17F, and IL-22. On the contrary, CD4⁺CD25⁺Foxp3⁺ cells reduced. In brief, our findings clearly show that: the drift balance of Th17/Treg is apparently in DSS-induced colitis. The increasing concentration of IL-17A, IL-17F, and IL-22, as well as the increasing Th17 and Th22 cells count, suggesting Th17 and Th22 are involved in the pathological process. Further studies are warranted to develop drugs, which are effective for colitis by targeting the Th17/Treg and Th22 pathways.

Keywords

dextran sodium sulfate colitis IL-17A IL-17F IL-22 Th17/Treg balance Th22

Introduction

Inflammatory bowel disease (IBD) is chronic remittent or progressive inflammatory conditions related to the mucosal immune system response to antigenic stimulation from the human intestinal microbiome on a background of genetic susceptibility.^1,2 The two most common forms are ulcerative colitis (UC) and Crohn’s disease (CD). Despite hundreds of studies, the etiology of IBD still remains ambiguous.

Animal models of IBD have been central to enhance the understanding of human disease and have made significant contributions to the development of powerful new therapies and drugs.^3,4 There are more than 50 different models of IBD used for studies Dextran sodium sulfate (DSS) induced colitis is one of the most widely used models of IBD historically, because it has similarities to human UC in etiology, pathology, pathogenesis, and therapeutic response.^5,6 DSS administration triggers intestinal inflammation by binding to medium-chain-length fatty acids present in the mouse colon, inducing disruption of colonic epithelial barrier.⁷ The ensuing tissue damage allows exposure of innate immune cells to commensal bacteria accompanied by a robust immune response to eliminate infiltrating pathogens and promote tissue healing.⁷

IBD was regarded as a kind of disease due to Th1/Th2 abnormal immunoregulation for a long time. T-helper cell (Th) 17, a new CD4+ T cell subset, has transformed our understanding of the IBD pathogenetic basis of an increasing number of chronic immune-mediated diseases.^8,9. The Th17 cells express cytokines interleukin (IL)-17A (commonly denoted IL-17), IL-17F, IL-21, IL-22, and IL-26; however, not all Th17 cells secrete all these cytokines, probably reflecting the heterogeneity of this Th cell subset.¹⁰ On one hand, Th17 cells have major effects on host protection against a wide spectrum of pathogens, especially at mucosal surfaces,^11,12 on the other hand, sustained activation of Th17 cells can also be potent mediators of colitis as well. Interestingly, regulatory T cells (Treg) have been found a fine balance with Th17 cells regulating by the concentration of transforming growth factor beta (TGFβ).¹²

Th22 cells, as the major source of IL-22, represent a T cell subset uniquely competent to regulate epidermal responses in inflammatory diseases.¹³ Unlike Th17, the cell is the second major source of IL-22. Th22 cells do not secrete IL-17.¹⁴ IL-22 belongs to the IL-10 family of cytokines and binds to a heterodimer composed of IL10 receptor (IL-10R) β chain and IL-22R. Despite a similar molecular structure and shared receptors, the bioavailability of IL-22 is also regulated by a soluble IL-22 binding protein (IL-22BP) that acts as a natural antagonist, and IL-22 signaling acts independently of IL-10, also triggers STAT3 and MAPK pathways.^13–15 Lauren A. Zenewicz et al. reported that colon epithelial cells are a target for IL-22 activity.¹⁶ They concluded that IL-10Rβ was ubiquitously expressed in the liver, spleen, skin, kidney, lung, colon, and small intestine; however, IL-22R was highly expressed in the colon and small intestine and to a lesser extent in the other tissues.¹⁶

Being interested in the balance of Th17/Treg in IBD, and the curious relationship between Th-22 and pathogenesis of IBD, we determined the change of Treg/Th17 balance, Th22 proportion, and the expression of Th17-related and Th22-related cytokines in DSS-induced colitis model.

Materials and methods

Mice and DSS-induced colitis model

C57BL/6 female mice (weight range, 20–22 g) were obtained from the Vital River Laboratories. All of the animal protocols were reviewed and agreed upon the Ethics Committee of Animal Experiments of Lanzhou University. Mice received one cycle (5 days) of drinking-water containing 3% dextran sulfate salt (DSS) (3600–5000 KDa, MP Biomedicals), beginning on day 1 of the experiment.¹⁷ The normal control mouse received tap water only. Body weights, stool consistency, and occult or gross bleeding were measured every 24 h. The colon and spleen were separated immediately after the last weight check.

Clinical assessments

The disease activity index scoring system involved a combination of various features: changes in weight, stool consistency, and occult or gross bleeding. The disease activity index was between 0 and 12 for each mouse. The disease activity index component was scored according to the following criteria:¹⁸ weight loss: 0, none; 1, 1–5%; 2, 5–10%; 3, 10–20%; 4, >20%. Stool consistency: 0, normal; 2, loose stools; 4, diarrhea. Occult or gross bleeding: 0, normal; 2, hemoccult; 4, gross bleeding.

Histopathological analysis and histological scoring

A specimen from the distal third of the colon was fixed overnight with 4% phosphate-buffered (pH 7.2) paraformaldehyde and embedded in paraffin. Sections were cut at 5 μm thickness in a longitudinal fashion and stained with hematoxylin and eosin (H&E).¹⁹ Three sections per slide were scored on a blind basis and histological analysis was performed on a blind basis as standard protocols. Specifically, colonic histology was scored as follows:²⁰ Inflammation: 0, none; 1, slight; 2, moderate; 3, severe. Extent: 0, none; 1, mucosa; 2, mucosa and submucosa; 3, transmural. Regeneration: 4, no tissue repair; 3, surface epithelium not intact; 2, regeneration with crypt depletion; 1, almost complete regeneration; 0, complete regeneration or normal tissue. Crypt damage: 0, none; 1, basal one-third damaged; 2, basal two-thirds damaged; 3, only surface epithelium intact; 4, entire crypt and epithelium lost. Percent involvement: 1, 1–25%; 2, 26–50%; 3, 51–75%; 4, 76–100%.

Isolation of cells and flow cytometry

Briefly, spleen was removed and carefully cleaned. Splenic lymphocyte cells were prepared from the spleen by forcing the organs through a 100 μm nylon mesh into Lymphocyte Separation Medium (Mouse) according to the manufacturer’s direction (dakewe). The following antibodies were used in flow cytometry analysis: PE anti-mouse CD4 (clone GK1.5), PE/Cy5 anti-mouse CD4 (clone RM4-5), FITC anti-mouse CD25 (clone 3C7), FITC anti-mouse IL-17A (clone TC11-18H10.1), PE anti-mouse FOXP3 (clone MF-14), all from Biolegend; and anti-human/mouse IL-22 APC (clone IL22JOP) from eBioscience. Cells were stimulated for 4 h with PMA (50 ng/mL, Sigma), ionomycin (750 ng/mL, Calbiochem), and BFA (10 ng/mL, Biolegend). Cells were fixed with fixation buffer (Biolegend) and permeabilized with permeabilization buffer (eBioscience) and incubated with antibodies (13). Cells were analyzed using FACSCalibur (BD Biosciences), and data were illustrated by CellQuest-Pro software (BD).

Cytokines quantification in serum

Mouse IL-22 (Dakewe), IL-17A (Dakewe), and IL-17F (Shyuanye) enzyme linked immunosorbent assay (ELISA) kits were used according to the manufacturers’ instructions.

Statistical analysis

Data values were expressed as mean values with their standard errors for each group. Statistical comparisons were performed using one-way ANOVA, as appropriate, with P <0.05 considered statistically significant.

Results

Weight loss in DSS-induced colitis

After receiving one cycle of drinking-water containing 3% DSS, mice tended to lose weight compared to control animals (study 2–5), as showed in Figure 1. We found that DSS-induced mice lost significantly body weight compared with drinking-water mice at day 5 (14.91 vs. 1.15%, P <0.001).

Figure 1.

Changes in body weight after dextran sulphate sodium (DSS) administration in C67BL/6 mice. Body weight change was measured by dividing body weight on a specified day by body weight at day 0 (starting body weight) and expressed in percentage. N = 9, ***P <0.001 versus control group at day 5.

Colon shortening in DSS-induced colitis

In this study, the total colon length becomes shortened in mice treated with DSS. As showed in Figure 2, the DSS administration significantly caused colon shortening compared to control mice at day 5 (10.50 vs. 11.45 cm, P <0.05).

Figure 2.

Colon length decreased after dextran sulphate sodium (DSS) administration in C67BL/6 mice. The colon length was measured on day 5 after administration of DSS. N = 9, mean values were significantly different compared control group at day 5: *P <0.05, **P <0.01.

Clinical colitis in DSS-induced colitis

Clinical symptoms such as loss of body weight, loose stools, and fecal blood appeared in DSS group, which are consistent with other studies.²¹ The clinical symptoms first occurred on day 3. Compared to control mice, DSS-induced mice increased significantly in the disease activity index at day 5 (7.40 vs. 1.20, P <0.001, Figure 3).

Figure 3.

Disease activity index (DAI) increased after dextran sulphate sodium (DSS) administration in C67BL/6 mice. DAI score was assessed on day 5 after administration of DSS. N = 9, ***P <0.001 versus control group at day 5.

The histological damage of colonic mucosa in DSS-induced colitis

Control group showed normal architecture with intact epithelium in colonic mucosa, while the DSS group showed severe damage to the surface epithelium, intense transmural inflammation, and submucosal neutrophils infiltration (Figure 4a and b). Quantification of these colonic histology results was shown in Fig 4e. DSS group had significantly (14.67 vs. 2.00, P <0.001, Figure 4e) higher colonic histology scores than the control mice.

Figure 4.

Histological pathology increased after dextran sulphate sodium (DSS) administration. (a) Control group, (b) DSS group (hematoxylin and eosin staining; magnification 200×). (c) Histological score. N = 9, ***P <0.001 versus control group at day 5.

Th17 and Treg cell populations in DSS-induced colitis

Plots are gated on CD4+ T cells were shown in Figure 5a. In DSS-induced colitis, CD4⁺IL-17A⁺IL-22⁻ cells (1.47 vs. 0.47%, P <0.05, Figure 5b) and CD4⁺IL-22⁺IL-17A⁻ cells (2.46 vs. 0.90%, P <0.05, Figure 5c) increased compared with the control group. On the contrary, CD4⁺CD25⁺Foxp3⁺ cells in the DSS group reduced compared with the control group (0.15 vs. 0.47%, P <0.05, Figure 5d).

Figure 5.

CD4⁺IL-22⁺IL-17A⁻ cells, CD4⁺IL-17A⁺IL-22⁻ cells and CD4⁺CD25⁺Foxp3⁺ cells production changes in dextran sulphate sodium (DSS)-induced colitis. (a) Shown are intracellular stainings for splenic lymphocyte cells conditions and after stimulation with PMA/ionomycin. (b-d) The data of flow cytometry analysis of CD4⁺IL-22⁺IL-17A⁻ cells (b), CD4⁺IL-17A⁺IL-22⁻ cells (c), and CD4⁺CD25⁺Foxp3⁺ cells (d). N = 9, mean values were significantly different compared control group at day 5: *P <0.05, ***P <0.001.

Cytokine levels in serum

To analyze the cytokine production change in serum during colitis, we investigated representative Th17 (IL-17A, IL-17F, and IL-22) cytokine levels by ELISA after 5 days of DSS administration. The level of IL-17A (235.33 vs. 142.05 pg/mL, P <0.05, Figure 6a), IL-17F (32.25 vs. 23.13 pg/mL, P <0.05, Figure 6b), and IL-22 (1895.96 vs. 1105.12 pg/mL, P <0.001, Figure 6c) in the DSS group showed a significant increase compared with the control group.

Figure 6.

IL-17A, IL-17F, and IL-22 production increased in dextran sulphate sodium (DSS)-induced colitis serum. (a) IL-17A concentration, (b) IL-17F concentration, (c) IL-22 concentration. N = 9, mean values were significantly different compared control group at day 5: *P <0.05, ***P <0.001.

Discussion

The present study detected the change of Treg/Th17 balance, Th22 proportion, and the expression of Th17- and Th22-related cytokines on the DSS-administrated mice. The experimental data showed that there are significantly difference between DSS-administrated mice and the control group in colitis clinical symptoms, Treg/Th17 balance, Th22 proportion, and IL-17A, IL-17F, L-22 concentration.

Animal models of IBD have contributed significantly to the present understanding of IBD, as they provided a platform through which some of these complex mechanisms could be systematically investigated, sometimes with manipulations and interventions, that would not have been possible with human studies.⁵ We chose the DSS-induced colitis model, which caused hematochezia, body weight loss, shortening of the intestine, mucosal ulcers, and infiltration of neutrophils.^22,23 In this study, DSS-induced colitis, made mice weight drops (14.91%, Figure 1), caused colon shrinkage (P <0.05, Figure 2), resulted in higher disease activity index (P <0.001, Figure 3) and colonic histology scores (P <0.001, Figure 4e). At the same time, we observed severe damage to the surface epithelium, intense transmural inflammation, and submucosal neutrophils infiltration in the colon.

Mice with acute DSS-induced colitis exhibit pathogenetic similarities to human IBD, particularly UC.^5,24 Insights into IBD are advancing rapidly owing to the discovery of new CD4+ T cell subsets. Dieleman reported in 1998 that the cytokine response in the DSS-induced colitis appears to be a Th1 and Th2 type with increased levels IFN-γ and IL-4 in inflamed colonic tissue compared to controls in SW mice.²⁰ In 2009, data indicated that DSS colitis switches from a Th1-Th17-mediated acute inflammation to a predominant Th2-mediated inflammatory response in the chronic state.²⁵ Whereafter, increasing the relative balance of Tregs to Th17 is a novel strategy for IBD, such as histone-deacetylase inhibitors that ameliorate DSS colitis through expansion of Tregs.^11,26 In 2009, Eyerich et al. have identified a subset of human Th cells that infiltrates the epidermis in individuals with inflammatory skin disorders and is characterized by the secretion of IL-22 and TNF-α, but not IFN-γ, IL-4, or IL-17.¹³ Recent genome-wide analysis carried out in the initial phase of DSS-induced colitis revealed that the IL-22/STAT3 axis enforces a gene profile in IEC that especially connects to the vital task of intestinal wound healing.²⁷ In the present study CD4⁺IL-17A⁺IL-22⁻ cells and CD4⁺IL-22⁺IL-17A⁻ cells increased (P <0.05, Figure 5b and c) and CD4⁺CD25⁺Foxp3⁺ cells reduced (P <0.05, Figure 5d) in DSS-induced colitis compared with the control group. The unusually low levels of CD4+CD25+Foxp3+ cells proportions (0.15 vs. 0.47%, Figure 5d) might result from extra needless stimulating with PMA, ionomycin, and BFA. These data suggested that in DSS-induced colitis the balance between Th17 and Treg cells shifted, and Th22 cells participated in colitis.

IL-17A and IL-17F belong to IL-17 family, as well as IL-17B-E. IL-22 is IL-10 family cytokine. IL-17F possesses the highest degree of homology with IL-17A, sharing similar functions through binding to the common cell surface receptor complex that is consisted of IL-17RA and IL-17RC.^24–28). IL-17A and IL-17F essentially contribute to the development of bowel inflammation, in contrast, biological roles of other IL-17 family members have not been fully characterized.²⁴ Both IL-17A and IL-17F have a redundant but highly pathogenic role in gut inﬂammation, and had to be deficient or neutralized to block disease after transfer of wild type CD4⁺CD45RB^hi T cells.^9,29 However, studies also have shown that IL-17A and IL-22 are produced at early stages in the cecum of mice with Citrobacter rodentium infection and are necessary for host defence against this pathogen.^10,30 Thus IL17A, IL-17F, and IL-22 are bifunctional in that they have both proinflammatory and protective effects on tissues depending on the inflammatory context.¹⁶ We found a significant increase in the level of IL-17A (P <0.05, Figure 6a), IL-17F (P <0.05, Figure 6B), and IL-22 (P <0.001, Figure 6c) in DSS-induced colitis. These findings validate a great deal of previous research on conformity; however, further research is needed to see the mechanism of IL-17A, IL-17F, and IL-22 in IBD.

Collectively, the drift balance of Th17/Treg is apparently in DSS-induced colitis. The increasing concentration of IL-17A, IL-17F, and IL-22, as well as the increasing Th17 and Th22 cells count, suggests that Th17 and Th22 are involved in the pathological process. Further studies are warranted to develop drugs targeting the Th17/Treg and Th22 pathways, by which these agents are able to protect against ulcerative colitis.

Footnotes

Acknowledgements

We thank Professors Hongyu Li and Jinbo Yang for help with flow cytometry and are grateful to Professor Qiang Chen (Lanzhou University) for animal husbandry.

Declaration of conflicting interests

The author(s) declared no potential conflicts of interest with respect to research, authorship, and/or publication of this article.

Funding

This work was supported by the foundation of the Key Laboratory for Gastrointestinal Diseases of Gansu Province (no. gswcky-2012-007).

References

Kwon

Kim

(2008) Glabridin, a functional compound of liquorice, attenuates colonic inflammation in mice with dextran sulphate sodium-induced colitis. Clinical & Experimental Immunology 151: 165–173.

Prideaux

Kamm

De Cruz

. (2012) Inflammatory bowel disease in Asia: A systematic review. Journal of Gastroenterology and Hepatology 27: 1266–1280.

Motavallian

Minaiyan

Rabbani

. (2012) Does cisapride, as a 5HT4 receptor agonist, aggravate the severity of TNBS-induced colitis in rat? Gastroenterology Research and Practice 2012: 362536.

Webb

(2014) Animal models of human disease: Inflammation. Biochemical Pharmacology 87: 121–130.

Solomon

Mansor

Mallon

. (2010) The dextran sulphate sodium (DSS) model of colitis: An overview. Comparative Clinical Pathology 19: 235–239.

De Fazio

Cavazza

Spisni

. (2014) Longitudinal analysis of inflammation and microbiota dynamics in a model of mild chronic dextran sulfate sodium-induced colitis in mice. World Journal of Gastroenterology 20: 2051–2061.

Gkouskou

Deligianni

Tsatsanis

. (2014) The gut microbiota in mouse models of inflammatory bowel disease. Frontiers in Cellular and Infection Microbiology 4: 28.

Harrington

Hatton

Mangan

. (2005) Interleukin 17–producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nature Immunology 6: 1123–1132.

Weaver

Elson

Fouser

. (2013) The Th17 pathway and inflammatory diseases of the intestines, lungs, and skin. Annual Review of Pathology 8: 477–512.

10.

Monteleone

Sarra

Pallone

. (2012) Th17-related cytokines in inflammatory bowel diseases: Friends or foes? Current Molecular Medicine 12: 592–597.

11.

Kaser

Zeissig

Blumberg

(2010) Inflammatory bowel disease. Annual Review of Immunology 28: 573–621.

12.

Wang

Friedrich

Hagemann

. (2014) Regulatory T cells promote a protective Th17-associated immune response to intestinal bacterial infection with C. rodentium. Mucosal Immunology 7: 1290–1301.

13.

Eyerich

Pennino

. (2009) Th22 cells represent a distinct human T cell subset involved in epidermal immunity and remodeling. Journal of Clinical Investigation 119: 3573–3585.

14.

Eyerich

Cavani

. (2010) IL-17 and IL-22: Siblings, not twins. Trends in Immunology 31: 354–361.

15.

Lejeune

Dumoutier

Constantinescu

. (2002) Interleukin-22 (IL-22) activates the JAK/STAT, ERK, JNK, and p38 MAP kinase pathways in a rat hepatoma cell line. Pathways that are shared with and distinct from IL-10. Journal of Biological Chemistry 277: 33676–3382.

16.

Zenewicz

Yancopoulos

Valenzuela

. (2008) Innate and adaptive interleukin-22 protects mice from inflammatory bowel disease. Immunity 29: 947–957.

17.

Katada

Yoshida

Suzuki

. (2008) Dextran sulfate sodium-induced acute colonic inflammation in angiotensin II type 1a receptor deficient mice. Inflammation Research 57: 84–91.

18.

Cooper

Murthy

Shah

. (1993) Clinicopathologic study of dextran sulfate sodium experimental murine colitis. Laboratory Investigation 69: 238–249.

19.

Jädert

Phillipson

Holm

. (2014) Preventive and therapeutic effects of nitrite supplementation in experimental inflammatory bowel disease. Redox Biology 2: 73–81.

20.

Dieleman

Palmen

Akol

. (1998) Chronic experimental colitis induced by dextran sulphate sodium (DSS) is characterized by Th1 and Th2 cytokines. Clinical & Experimental Immunology 114: 385–391.

21.

Melgar

Karlsson

Michaëlsson

(2005) Acute colitis induced by dextran sulfate sodium progresses to chronicity in C57BL/6 but not in BALB/c mice: Correlation between symptoms and inflammation. American Journal of Physiology: Gastrointestinal and Liver Physiology 288: G1328–1338.

22.

Okayasu

Hatakeyama

Yamada

. (1990) A novel method in the induction of reliable experimental acute and chronic ulcerative colitis in mice. Gastroenterology 98: 694–702.

23.

Jurjus

Khoury

Reimund

J-M

(2004) Animal models of inflammatory bowel disease. Journal of Pharmacological and Toxicological Methods 50: 81–92.

24.

Ito

Kita

Shin-Ya

. (2008) Involvement of IL-17A in the pathogenesis of DSS-induced colitis in mice. Biochemical and Biophysical Research Communications 377: 12–16.

25.

Alex

Zachos

Nguyen

. (2009) Distinct cytokine patterns identified from multiplex profiles of murine DSS and TNBS-induced colitis. Inflammatory Bowel Disease 15: 341–352.

26.

Tao

de Zoeten

Özkaynak

. (2007) Deacetylase inhibition promotes the generation and function of regulatory T cells. Nature Medicine 13: 1299–1307.

27.

Pickert

Neufert

Leppkes

. (2009) STAT3 links IL-22 signaling in intestinal epithelial cells to mucosal wound healing. Journal of Experimental Medicine 206: 1465–1472.

28.

Toy

Kugler

Wolfson

. (2006) Cutting edge: Interleukin 17 signals through a heteromeric receptor complex. Journal of Immunology 177: 36–39.

29.

Leppkes

Becker

Ivanov II . (2009) RORγ-expressing Th17 cells induce murine chronic intestinal inflammation via redundant effects of IL-17A and IL-17F. Gastroenterology 136: 257–267.

30.

Geddes

Rubino

Magalhaes

. (2011) Identification of an innate T helper type 17 response to intestinal bacterial pathogens. Nature Medicine 17: 837–844.